# US 2013/0158260 A1 · Aminodihydrothiazine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158260 A1
- Document ID: US20130158260A1
- Status: Published application
- Kind: A1
- Application number: 13/768,557
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2005-10-25
- Assignees: Shionogi & Co., Ltd.
- Inventors: Naotake KOBAYASHI; Kazuo UEDA; Naohiro ITOH; Shinji SUZUKI; Gaku SAKAGUCHI; Akira KATO; Akira YUKIMASA; Akihiro HORI; Yuji KORIYAMA; Hidekazu HARAGUCHI; Ken YASUI; Yasuhiko KANDA
- Web page: https://patentgrep.com/patent/US20130158260A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 31/426: 1,3-Thiazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/14: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
- C07D 239/24: having three or more double bonds between ring members or between ring members and non-ring members
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 265/08: having one double bond between ring members or between a ring member and a non-ring member
- C07D 277/18: Nitrogen atoms
- C07D 279/06: not condensed with other rings
- C07D 279/08: condensed with carbocyclic rings or ring systems
- C07D 279/12: not condensed with other rings
- C07D 281/02: Seven-membered rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene; X is S, O, or NR′; R1 is a hydrogen atom or lower alkyl; R2a, R2b, R3a, R3b, R4a and R4b is each independently a hydrogen atom, halogen, or hydroxy etc.; n and m are each independently an integer of 0 to 3; n+m is an integer of 0 to 3; R5 is a hydrogen atom or substituted lower alkyl; its pharmaceutically acceptable salt, or a solvate thereof.

## Claims

### Claim 1

A compound represented by the general formula (I):
wherein ring A is an optionally substituted heterocyclic group,
Alk1 is lower alkylene or lower alkenylene;
R1 is a hydrogen atom, lower alkyl, or acyl;
X is O, or NR1;
R1 is a hydrogen atom or lower alkyl;
R2a and R2b are each independently a hydrogen atom, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted amino, optionally substituted amidino, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted carbamoylcarbonyl, optionally substituted lower alkylsulfonyl, optionally substituted arylsulfonyl, an optionally substituted carbocyclic group, or an optionally substituted heterocyclic group;
R3a, R3b, R4a, and R4b are each independently a hydrogen atom, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted acyl, carboxy, optionally substituted lower alkoxycarbonyl, optionally substituted amino, optionally substituted carbamoyl, an optionally substituted carbocyclic group, or an optionally substituted heterocyclic group;
n and m are each independently an integer of 0 to 3;
n+m is an integer of 1 to 3;
each R3a, each R3b, each R4a, and each R4b may be independently different;
R5 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, an optionally substituted carbocyclic group, an optionally substituted heterocyclic group;
R5 and ring A can be taken together to form
wherein R5a and R5b are each independently a hydrogen atom or lower alkyl;
s is an integer of 1 to 4;
each R5a and each R5b may be different;
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound according to claim 1, wherein n is 2 and m is 0, its pharmaceutically acceptable salt or a solvate thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein E is a bond, its pharmaceutically acceptable salt or a solvate thereof.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

The compound according to claim 1,
wherein R5 is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, an optionally substituted carbocyclic group, or an optionally substituted heterocyclic group,
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim 9 (depends on 1)

The compound according to claim 1,
wherein R2a is a hydrogen atom; R2b is a hydrogen atom, optionally substituted lower alkyl, optionally substituted acyl, optionally substituted lower alkylsulfonyl, or optionally substituted amidino,
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim 10 (depends on 1)

The compound according to claim 1,
wherein NR2aR2b is represented by the formula:
[Chemical formula 6]
R6, R7, and R8 are each independently a hydrogen atom, lower alkyl, or acyl;
Y is optionally substituted lower alkylene, optionally substituted lower alkenylene, or
optionally substituted lower alkynylene;
Z is O or S;
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim at position 9

11-15. (canceled)

### Claim 16 (depends on 1)

The compound according to claim 1,
wherein R5 is C1 to C3 alkyl,
its pharmaceutically acceptable salt, or a solvate thereof/

### Claim 17 (depends on 1)

The compound according to claim 1,
wherein R5 is methyl,
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim 18 (depends on 1)

The compound according to claim 1,
wherein R3a and R3b are each independently a hydrogen atom, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, or optionally substituted aryl,
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim 19 (depends on 1)

The compound according to claim 1,
wherein all of R3a and all of R3b are hydrogen atoms,
its pharmaceutically acceptable salt, or a solvate thereof.

### Claim at position 14

20-21. (canceled)

### Claim 22 (depends on 1)

The compound according to claim 1, wherein X is O, its pharmaceutically acceptable salt or a solvate thereof.

### Claim 23 (depends on 1)

The compound according to claim 1, wherein ring A is substituted pyridyl, its pharmaceutically acceptable salt or a solvate thereof.
